|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
So far, no clear histopathological and molecular features of breast tumours occurring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumour signature may help in patient management.
|
29665859 |
2018 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The analysis of additional breast tumors from ten BC families in which a germline ATM mutation had been identified revealed a high frequency of wild-type allele loss.
|
28691344 |
2017 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used qRT-PCR assay to quantify mRNA levels of ATM gene in 454 breast tumours from patients with known clinical/pathological status and outcome; reverse phase protein arrays (RPPA) were used to assess the levels of ATM and 14 proteins in 233 breast tumours.
|
25742469 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Analysis of loss of heterozygosity (LOH) in 18 breast tumors from women carrying likely pathogenic rare sequence variants revealed no consistent pattern of loss of the ATM variant.
|
21787400 |
2011 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Our findings provide the first experimental evidence that ATM is a human breast tumor suppressor.
|
20177072 |
2010 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.
|
18264724 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We have found that carriers of an ATM missense mutation, who were treated with radiotherapy for the first breast tumour, developed their second tumour on average in a 92-month interval compared to a 136-month mean interval for those CBC patients who neither received RT nor carried a germline variant, (p = 0.029).
|
17393301 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Association of common ATM variants with familial breast cancer in a South American population.
|
18433505 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?
|
17351744 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?
|
18557994 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.
|
18701470 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
|
17166884 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
To investigate whether aberrant methylation of the ATM promoter or loss of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) may be the underlying causes of reduced ATM protein levels often seen in breast tumours.
|
17593081 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy.
|
17517479 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ATM variants and cancer risk in breast cancer patients from Southern Finland.
|
16914028 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Fifty-two breast tumors from 51 patients, 38 of them with concomitant in situ component (CIS), were analyzed by immunohistochemistry for the expression of ATM.
|
16329039 |
2006 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling.
|
17001622 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ATM and breast cancer susceptibility.
|
16998505 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.
|
16832357 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.
|
16652348 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression.
|
16636671 |
2006 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Two ATM variants and breast cancer risk.
|
15880680 |
2005 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Loss of heterozygosity at the ATM locus has been reported in 30-40% of breast tumours and 50-70% show altered ATM protein levels.
|
16112413 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Cancer risks and mortality in heterozygous ATM mutation carriers.
|
15928302 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families.
|
15390180 |
2005 |